Skip to main
KLRS

Allovir Inc (KLRS) Stock Forecast & Price Target

Allovir Inc (KLRS) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kalaris Therapeutics is positioned to potentially compete successfully in the market of anti-VEGF therapies for retinal diseases, with their drug TH103 showing promising results in clinical trials and potential for longer-lasting and increased anti-VEGF activity. However, they face competition from other companies also developing anti-VEGF drugs, and the need for additional funding to bring their product to market. The recent acquisition of Allergan by AbbVie highlights the importance of treatments for intraocular inflammation, which could also be a benefit for Kalaris Therapeutics as TH103 has shown minimal inflammation in their studies.

Bears say

Kalaris Therapeutics is a clinical-stage biopharmaceutical company with a potentially game-changing drug, TH103, in its pipeline for wet AMD treatment. With its unique mechanism of action and potential for longer-lasting VEGF suppression, TH103 has the potential to gain a significant market share in the $15B+ wet AMD industry upon its projected launch in 2032. However, it faces competition from other treatments in development, and its success will depend on its safety and efficacy compared to already established therapies like Lucentis and Eylea.

Allovir Inc (KLRS) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allovir Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allovir Inc (KLRS) Forecast

Analysts have given Allovir Inc (KLRS) a Buy based on their latest research and market trends.

According to 5 analysts, Allovir Inc (KLRS) has a Buy consensus rating as of Aug 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allovir Inc (KLRS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.